Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial

Official title:

A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01500694
• Other study ID #: SPD503-318
• Secondary ID: 2011-004668-31
• Status: Completed
• Phase: Phase 3
• Start date: March 20, 2012
• Est. completion date: September 15, 2015

Study information

• Verified date: May 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

For subjects in Europe that have already participated in either Study SPD503-315 or SPD503-316. This is an extension study that will allow participants access to Extended-release Guanfacine Hydrochloride (HCl) for up to 2 years. This study will help the sponsor evaluate long-term safety and tolerability of Extended-release Guanfacine HCl (SPD503).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 215
• Est. completion date: September 15, 2015
• Est. primary completion date: September 15, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Subjects where Study SPD503-318 was not available at the time of their final visit in the antecedent study (SPD503-315 or SPD503-316), may still be screened unless they are well-controlled on another ADHD medication with acceptable tolerability and the parent/caregiver is satisfied with their current ADHD medication.

2. Subject satisfied all entry criteria for the antecedent study (SPD503 315 or SPD503-316).

3. Subject who is a female of child-bearing potential (FOCP), defined as >9 years of age or <9 years of age and is post-menarchal, must have a negative serum beta human chorionic gonadotropin (hCG) pregnancy test at the Screening Visit (Visit 1) and a negative urine pregnancy test at the Baseline Visit (Visit 2) and agree to comply with any applicable contraceptive requirements of the protocol.

4. Subject's parent or legally authorised representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related procedures.

5. Subject and parent/LAR are willing, able, and likely to fully comply with all the testing and requirements defined in this protocol, including oversight of dosing. Specifically, the parent/LAR must be available upon awakening, to dispense the dose of investigational product for the duration of the study.

6. Subject has a supine and standing blood pressure (BP) measurement within the 95th percentile for age, sex, and height.

7. Subject is functioning at an age-appropriate level intellectually, as deemed by the Investigator.

8. Subject is able to swallow intact tablets.

Exclusion Criteria:

1. Subject has any current, controlled (requiring a prohibited medication or behavioural modification program) or uncontrolled, co-morbid psychiatric diagnosis (except oppositional defiant disorder), including any severe comorbid Axis II disorders or severe Axis I disorders such as post traumatic stress disorder, bipolar illness, psychosis, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse disorder, or other symptomatic manifestations or lifetime history of bipolar illness, psychosis or conduct disorder that, in the opinion of the Investigator, contraindicate treatment with SPD503 or confound efficacy or safety assessments. The Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime version (K-SADS-PL) rating from the antecedent study should be reviewed to confirm diagnosis, if necessary.

2. Subject who early terminated from Study SPD503-315 or Study SPD503-316 for protocol non-adherence, subject non-compliance, an AE, SAE, or withdrawal by subject.

3. Subject experienced any clinically significant AE in their prior SPD503 study (SPD503-315 or SPD503 316) that, in the opinion of the Investigator, would preclude exposure to SPD503.

4. Clinically important abnormality on urine drug and/or alcohol screen at the Screening Visit (Visit 1).

5. Subject has taken any investigational product as follows: last dose of investigational product in Study SPD503-315 within 7 days prior to the Baseline Visit (Visit 2); investigational product in Study SPD503 316 within 30 days prior to the Baseline Visit (Visit 2); any other investigational product within 30 days prior to the Baseline Visit (Visit 2) or any other ADHD medication within 30 days prior to Baseline Visit (Visit 2).

6. Subject is significantly overweight based on Center for Disease Control and Prevention Body Mass Index (BMI)-for-age sex-specific charts at the Screening Visit (Visit 1). Significantly overweight is defined as a BMI >95th percentile.

7. Children aged 6 12 years with a body weight of less than 25.0kg or adolescents aged 13 years and older with a body weight of less than 34.0kg at the Screening Visit (Visit 1).

8. Subject has any condition or illness including clinically significant abnormal laboratory values at the Screening Visit (Visit 1) which, in the opinion of the Investigator, represents an inappropriate risk to the subject and/or could confound the interpretation of the study.

9. Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator.

10. Subject has clinically significant ECG findings, as judged by the Investigator with consideration of the central ECG laboratory's interpretation, at the Baseline Visit (Visit 2).

11. Subject has a known or suspected allergy, hypersensitivity, or clinically significant intolerance to guanfacine hydrochloride, or any components found in SPD503.

12. Subject has a history of alcohol or other substance abuse or dependence, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text RevisionÒ (DSM-IV-TRÒ; with the exception of nicotine) within the last 6 months.

13. Subject has a history of a seizure disorder (other than a single childhood febrile seizure occurring before the age of 3 years) or the presence of a serious tic disorder including Tourette's syndrome.

14. Subject has a known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems (eg, clinically significant heart block), exercise related cardiac events including syncope and pre syncope, or clinically significant bradycardia.

15. Subject with orthostatic hypotension or a known history of controlled or uncontrolled hypertension.

16. Current use of any prohibited medication or other medications, including herbal supplements, that affect BP or heart rate or that have central nervous system (CNS) effects or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (inhaled bronchodilators are permitted) or a history of chronic use of sedating medications (ie, antihistamines) in violation of the protocol specified washout criteria at the Baseline Visit (Visit 2).

17. Subject has a medical condition, other than ADHD, that requires treatment with medications that have CNS effects and/or affect performance.

18. Subject is female and is pregnant or currently lactating.

19. Subject failed screening or was previously enrolled in this study.

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder (ADHD)
• Hyperkinesis

Intervention

Drug:
• Extended-release Guanfacine HCl (Intuniv, SPD503)
Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age

Locations

Country	Name	City	State
Austria	Medizinische Universitat Graz Univ fur Kinder	Graz
Austria	Institut fur Psychosomatik	Wien
Belgium	Universitaire Kinder-end Jeugdpsychatrie	Hoboken
Belgium	Centre de Reference Neuropediatrique Multidisciplinaire	Namur
Belgium	Huisartspraktijk Jaak Mortelmans	Oostham
Belgium	Zlekenhuis Inkendaal Koninklijke Instelling v.z.w.	Vlezenbeek
France	Centre Hospitalier Universitaire Amiens	Amiens Cedex	Picardie
France	Centre Hospitalier Charles Perrens	Bordeaux Cedex
France	Hopital Gui de Chauliac	Montpellier
Germany	Dr. med. Andreas Mahler	Achim
Germany	Emovis GmbH	Berlin
Germany	Sozialpsychitrisches Zentrum	Dorsten
Germany	Klinik und Poliklinik fur Kinder-und Jugendpsychiatrie un psychotherapie	Dresden
Germany	Dr. med Walter Robert Otto	Fulda
Germany	Dr. med. Christian Wolff	Hagen
Germany	Dr. med Friedrich Kaiser	Hamburg
Germany	Institut fur Ganzheitliche Medizin und Wissenschaft GmbH	Huttenberg
Germany	Friedrich Schiller Universitat Jena Klinik fur Kinder und Jugendpsychiatrie	Jena
Germany	Universitatsmedizin der Johannes-Gutenberg-Universitat	Mainz
Germany	Kinder-und Jugendpsychiatrische Praxis	Munchen
Germany	Somni bene GmbH Institut fur Medizinische Forschung und Schlatmedizin	Schwerin
Germany	Universitatsklinik Ulm	Ulm
Ireland	Our Lady's Children's Hospital	Crumlin	Dublin
Italy	Azienda Ospedaliero-Universitaria Policlinico-Vittorio	Catania
Italy	Azienda Ospedallera Fatebenefratelli	Milano
Italy	Azienda Ospedallera G Salvini - Ospedale Di Circolo de RHO	Milano
Italy	U.O di Neuropsichiatria Infantile	Padova
Italy	IRCCS Fondazione Stella Maris	Pisa
Italy	Ospedale Policlinico GB Rossi	Verona
Netherlands	Flevo Research	Almere
Netherlands	Mondriaan Zorggroep	Heerlen
Poland	Centrum Badari Klinicznych House Sp. z.o.o.	Gdansk
Poland	NZOZ Gdanskie Centrum Zdrowia	Gdansk
Poland	Gabinet Psychiatrii Doroslych, Dzieci i Mlodziezy	Torun
Poland	Indywidualna Specjalisyczna Praktyka Lekarska	Torun
Poland	Contrum Neurospychiatrii Neuromed	Wroclaw
Romania	Spitalul Clinic de Psihiatrie	Bucuresti
Romania	Spitalul Clinic de Psihiatrie Socoia	Iasi
Romania	Spitalul Clinic de Urgenta pentru Copli	Timisoara	Timis
Spain	Hospital Universitani Vall d'Hebron	Barcelona
Spain	Hospital Fundacion Alcorcon	Madrid
Spain	Hospital Infanta Leonor, Servicio de Psiquiatria	Madrid
Spain	Hospital Son Llatzer	Palma de Mallorca
Spain	Unidad de Salud Mental Infanto Juvenil	Santander
Spain	Hospital Mutua de Terrassa	Terrassa	Barcelona
Spain	Instituto Valenciano de Neurologia Pediatrica	Valencia
Sweden	Drottning Silvias Barnsjukhus	Goteborg
Ukraine	Regional Clinical Psychiatric Hospital	Donetsk
Ukraine	Institute of Health Care for Children and Teenagers	Kharkiv
Ukraine	Institute of Neurology, Psychiatry and Narcology	Kharkov
Ukraine	Lviv Regional Clinical Psychiatric Hospital	Lviv
Ukraine	Odesa Regional Psychoneurological Dispensary	Odesa
Ukraine	Poltava Regional Clinical Psychiatric Hospital	Poltava
Ukraine	Vinnitsya regional psychoneurological hospital	Vinnytsia
United Kingdom	The Children's Centre	Norwich
United Kingdom	Centenary House Child and Adolescent Mental Health Services	Sheffield
United Kingdom	Ryegate Children's Centre	Sheffield
United Kingdom	Lister Hospital	Stevenage	Herfordshire
United Kingdom	Queen Elizabeth II Hospital - Howlands	Welwyn Garden City	Herfordshire
United Kingdom	Alder Hey Children's NHS Foundation Trust	West Derby	Liverpool

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Countries where clinical trial is conducted

Austria,  Belgium,  France,  Germany,  Ireland,  Italy,  Netherlands,  Poland,  Romania,  Spain,  Sweden,  Ukraine,  United Kingdom, 

References & Publications (1)

Huss M, Dirks B, Gu J, Robertson B, Newcorn JH, Ramos-Quiroga JA. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2018 Oct;27(10):1283-1294. doi: 10.1007/s00787-018-1113-4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Mean Systolic Blood Pressure at Final Assessment	Systolic Blood pressure was measured at supine and standing position and mean supine systolic blood pressure was reported here. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication [Visit 19/Early Termination (ET)/Day 714].	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
Primary	Change From Baseline in Mean Diastolic Blood Pressure at Final Assessment	Diastolic Blood pressure was measured at supine and standing position and mean supine diastolic blood pressure was reported here. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
Primary	Change From Baseline in Mean Supine Pulse at Final Assessment	Pulse was measured at supine and standing position and mean supine pulse was reported here. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
Primary	Change From Baseline in Mean Height at Final Assessment	Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
Primary	Change From Baseline in Mean Weight at Final Assessment	Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
Primary	Change From Baseline in Electrocardiogram Result (QRS Interval) at Final Assessment	Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
Primary	Change From Baseline in Electrocardiogram Result (QT Interval) at Final Assessment	Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
Primary	Number of Participants With Suicidal Behavior and / or Ideation ("Yes" Response) on the Columbia Suicide Severity Rating Scale (C-SSRS)	C-SSRS is a clinician rated assessment of suicidal behavior and / or intent categorized as: Suicidal behavior=a "yes" response to any of 5 suicidal behavior questions (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide); Suicidal ideation=a "yes" response to any one of 5 suicidal ideation questions which includes wish to be dead, and 4 different categories of active suicidal ideation (thought, thought with method, thought with intent, thought with plan and intent).	Final Assessment (last non missing data/up to Day 714)
Secondary	Change From Baseline in Attention-deficit and Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) - Total Score at Final Assessment	ADHD-RS-IV was developed to measure the behaviours of children with ADHD with 18 items. Each item is scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items may be grouped into 2 subscales: hyperactivity/impulsivity (even numbered items 2-18) and inattentiveness (odd numbered items 1-17) with possible score range from 0 (no symptoms) to 27 (most severe symptoms). The ADHD-RS-IV possible total scores range from 0 (no symptoms) to 54 (most severe symptoms). Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
Secondary	Number of Participants Assessed With Clinical Global Impression Severity of Illness (CGI-S) Scale	The CGI-S evaluate each participant's severity and improvement over time. The severity of a participant's condition is rated on a 7-point scale ranging from 1 to 7. The scale measures 0 = Not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill (BL-MI), 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill participant. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).	Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)